Brought to you by 
Microbia completes $50mm private financing
08 Mar 2007
Executive Summary
Microbia (gastrointestinal and cardiovascular therapeutics) has raised $50mm through its Series F venture round led by Ridgeback Capital. New investor Morgan Stanley Investment Management was joined by previous backers. The company will use the proceeds for three Phase II studies of linaclotide for functional gastrointestinal disorders, including chronic constipation and constipation-predominant irritable bowel syndrome, and MD0727 for hypercholesterolemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Microbia completes $50mm private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice